Safety of Bevacizumab in Patients with Metastatic Breast Cancer

Publisher： Karger

E-ISSN： 1423-0232|80|5-6|314-325

ISSN： 0030-2414

Source： Oncology, Vol.80, Iss.5-6, 2011-07, pp. : 314-325

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Improvement of Safety Profile of Docetaxel by Weekly Administration in Patients with Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 30, Iss. 8-9, 2007-09 ,pp. : 436-441

Karger

Access to resources Recommend Favorite

An Open-Label Safety Study of First-Line Bevacizumab in Combination with Standard Chemotherapy in Chinese Patients with Metastatic Colorectal Cancer Treated in an Expanded Access Program in Taiwan

By  

Oncology, Vol. 84, Iss. 5, 2013-03 ,pp. : 299-304

Karger

Access to resources Recommend Favorite

Safety Verification Trials of mFOLFIRI and Sequential IRIS + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients

By  

Oncology, Vol. 83, Iss. 2, 2012-07 ,pp. : 101-107

Karger

Access to resources Recommend Favorite

Final Safety and Efficacy Analysis of a Phase I/II Trial with Imatinib and Vinorelbine for Patients with Metastatic Breast Cancer

By  

Oncology, Vol. 87, Iss. 5, 2014-08 ,pp. : 300-310

Karger

Access to resources Recommend Favorite

Efficacy and Safety of S-1 in Patients with Metastatic Breast Cancer: Retrospective Review in a Single Institution

By  

Oncology, Vol. 79, Iss. 3-4, 2011-03 ,pp. : 273-277

Karger

Access to resources Recommend Favorite